Objective Changes in Motor Function During Placebo Treatment in PD
Neurol 54:710-714, Goetz,C.G.,et al, 2000
What Contributes to Quality of Life in Patients with Parkinson's Disease?
JNNP 69:308-312,289, Schrag,A. et al, 2000
Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999
Comparative Effects of Unilateral and Bilateral Subthalamic Nucleus Deep Brain Stimulation
Neurol 53:561-566, Kumar,R.,et al, 1999
Assessment of Motor Function After Stereotactic Pallidotomy
Neurol 50:266-270, Ondo,W.G.,et al, 1998
Double-Blind Evaluation of Subthalamic Nucleus Deep Brain Stimulation in Advanced Parkinson's Disease
Neurol 51:850-855, Kumar,R.,et al, 1998
Treatment of Advanced Parkinson's Disease by Posterior GPi Pallidotomy:1-Year Results of a Pilot Study
Ann Neurol 40:355-366, 3411996., Baron,M.S.,et al, 1996
Unilateral Transpl of Human Fetal Mesencephalic Tissue Into the Caudate Nucleus of Pts with Parkinson's
NEJM 327:1541-1548, Spencer,D.D.,et al, 1992
Survival of Implanted Fetal Dopamine Cells & Neuro Improvement 12 to 46 Months after Transpl for Parkinson's
NEJM 327:1549-1555, 15891992., Freed,C.R.,et al, 1992
Bilateral Fetal Mesencephalic Grafting in Two Patients with Parkinsonism Induced by MPTP
NEJM 327:1556-1563, 15891992., Widner,H.,et al, 1992
Does Ageing Aggravate Parkinsonisn Disability?
JNNP 54:780-782, Blin,J.,et al, 1991